Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol.
Naoki HosogayaTakahiro TakazonoKenji OtaRieko KiyaYumi ShiraiRina KawasakiHiroshi YanoShinpei MorimotoRumiko NakaoYumiko KanamaruYukari YoshinoYasuyuki IshikawaChizu FukushimaHiroshi YamamotoKoichi IzumikawaKatsunori YanagiharaHiroshi MukaePublished in: Medicine (2023)
NHCAP is a common pneumonia in clinical settings and a notable pneumonia whose mortality is high compared to community-acquired pneumonia. The present study showed the efficacy and safety of LSFX against NHCAP, which could lead to a larger number of therapeutic options for NHCAP.
Keyphrases
- community acquired pneumonia
- open label
- clinical trial
- study protocol
- healthcare
- phase ii
- randomized controlled trial
- phase iii
- mental health
- cardiovascular events
- respiratory failure
- quality improvement
- risk factors
- radiation therapy
- type diabetes
- health information
- health insurance
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome